IO Biotech Inc
IOBT
Company Profile
Business description
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Contact
Ole Maaloes Vej 3
Copenhagen NDK-2200
DNKT: +45 70702980
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
78
Stocks News & Analysis
stocks
Does SpaceX’s sky-high valuation make sense?
SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.
stocks
ASX healthcare leader sees further cuts to fair value
Fiercer competition expected to squeeze margins.
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.80 | 20.70 | 0.23% |
| CAC 40 | 7,968.20 | 25.29 | -0.32% |
| DAX 40 | 23,576.94 | 391.69 | -1.63% |
| Dow JONES (US) | 47,706.51 | 34.29 | -0.07% |
| FTSE 100 | 10,311.94 | 100.30 | -0.96% |
| HKSE | 25,898.76 | 61.14 | -0.24% |
| NASDAQ | 22,697.10 | 1.16 | 0.01% |
| Nikkei 225 | 55,025.37 | 776.98 | 1.43% |
| NZX 50 Index | 13,293.13 | 198.76 | 1.52% |
| S&P 500 | 6,781.48 | 14.51 | -0.21% |
| S&P/ASX 200 | 8,743.50 | 19.40 | 0.22% |
| SSE Composite Index | 4,133.43 | 10.29 | 0.25% |